152 related articles for article (PubMed ID: 31832391)
1. Estimating the Fiscal Costs of Osteoporosis in Korea Applying a Public Economic Perspective.
Connolly MP; Panda S; Kim HY
J Bone Metab; 2019 Nov; 26(4):253-261. PubMed ID: 31832391
[TBL] [Abstract][Full Text] [Related]
2. Estimating the broader fiscal consequences of acute hepatic porphyria (AHP) with recurrent attacks in Belgium using a public economic analytic framework.
Connolly MP; Kotsopoulos N; Vermeersch S; Patris J; Cassiman D
Orphanet J Rare Dis; 2021 Aug; 16(1):346. PubMed ID: 34348763
[TBL] [Abstract][Full Text] [Related]
3. Estimating the public economic consequences of introducing varenicline smoking cessation therapy in South Korea using a fiscal analytic framework.
Connolly MP; Baker CL; Kotsopoulos N
J Med Econ; 2018 Jun; 21(6):571-576. PubMed ID: 29376747
[TBL] [Abstract][Full Text] [Related]
4. Assessing the Fiscal Burden of Obesity in Canada by Applying a Public Economic Framework.
Kotsopoulos N; Connolly MP
Adv Ther; 2024 Jan; 41(1):379-390. PubMed ID: 37979088
[TBL] [Abstract][Full Text] [Related]
5. The public economic burden of suboptimal type 2 diabetes control upon taxpayers in Sweden: Looking beyond health costs.
Kotsopoulos N; Connolly MP; Willis M; Nilsson A; Ericsson Å; Baker-Knight J
Diabetes Obes Metab; 2022 Jun; 24(6):1038-1046. PubMed ID: 35137507
[TBL] [Abstract][Full Text] [Related]
6. Estimating the public economic consequences of cardiovascular disease-attributable events and evolocumab treatment in Australia.
Kotsopoulos N; Connolly MP; Li J
J Med Econ; 2021; 24(1):123-130. PubMed ID: 33464137
[TBL] [Abstract][Full Text] [Related]
7. Estimating the fiscal impact of rare diseases using a public economic framework: a case study applied to hereditary transthyretin-mediated (hATTR) amyloidosis.
Connolly MP; Panda S; Patris J; Hazenberg BPC
Orphanet J Rare Dis; 2019 Sep; 14(1):220. PubMed ID: 31533773
[TBL] [Abstract][Full Text] [Related]
8. Estimating the Fiscal Consequences of National Immunization Programs Using a "Government Perspective" Public Economic Framework.
Connolly MP; Kotsopoulos N
Vaccines (Basel); 2020 Sep; 8(3):. PubMed ID: 32887265
[TBL] [Abstract][Full Text] [Related]
9. The Hidden Economic Consequences of Migraine to the UK Government: Burden-of-Disease Analysis Using a Fiscal Framework.
Martins R; Large S; Russell R; Surmay G; Connolly MP
J Health Econ Outcomes Res; 2023; 10(2):72-81. PubMed ID: 37808457
[No Abstract] [Full Text] [Related]
10. Comparing the Fiscal Consequences of Controlled and Uncontrolled Osteoarthritis Pain Applying a UK Public Economic Perspective.
Martins R; Kotsopoulos N; Kosaner Kließ M; Beck C; Abraham L; Large S; Schepman P; Connolly MP
J Health Econ Outcomes Res; 2021; 8(1):127-136. PubMed ID: 34239946
[No Abstract] [Full Text] [Related]
11. The fiscal consequences of public health investments in disease-modifying therapies for the treatment of multiple sclerosis in Sweden.
Kotsopoulos N; Connolly MP; Dort T; Kavaliunas A
J Med Econ; 2020 Aug; 23(8):831-837. PubMed ID: 32400258
[No Abstract] [Full Text] [Related]
12. The long-term fiscal impact of funding cuts to Danish public fertility clinics.
Connolly MP; Postma MJ; Crespi S; Andersen AN; Ziebe S
Reprod Biomed Online; 2011 Dec; 23(7):830-7. PubMed ID: 22033399
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the Fiscal Costs and Consequences of Alzheimer's Disease in Germany: Microsimulation of Patients' and Caregivers' Pathways.
Martins R; Kotsopoulos N; Michalowsky B; Pemberton-Ross P; Urbich M; Connolly MP
J Prev Alzheimers Dis; 2022; 9(4):758-768. PubMed ID: 36281681
[TBL] [Abstract][Full Text] [Related]
14. Fiscal Impact of Smoking Cessation in Thailand: A Government Perspective Cost-Benefit Analysis.
Connolly MP; Kotsopoulos N; Suthipinijtham P; Rungruanghiranya S
Asia Pac J Public Health; 2018 May; 30(4):342-350. PubMed ID: 29667916
[TBL] [Abstract][Full Text] [Related]
15. The Lifetime Burden of Schizophrenia as Estimated by a Government-Centric Fiscal Analytic Framework.
Martins R; Kadakia A; Williams GR; Milanovic S; Connolly MP
J Clin Psychiatry; 2023 Aug; 84(5):. PubMed ID: 37555674
[No Abstract] [Full Text] [Related]
16. Modeling the fiscal costs and benefits of alternative treatment strategies in the United Kingdom for chronic hepatitis C.
Connolly MP; Kotsopoulos N; Ustianowski A
J Med Econ; 2018 Jan; 21(1):19-26. PubMed ID: 28830254
[TBL] [Abstract][Full Text] [Related]
17. The impact of rotavirus vaccination on discounted net tax revenue in Egypt: a government perspective analysis.
Connolly MP; Topachevskyi O; Standaert B; Ortega O; Postma M
Pharmacoeconomics; 2012 Aug; 30(8):681-95. PubMed ID: 22788259
[TBL] [Abstract][Full Text] [Related]
18. National healthcare budget impact analysis of the treatment for osteoporosis and fractures in Korea.
Yi H; Ha YC; Lee YK; Lim YT
J Bone Metab; 2013 May; 20(1):17-23. PubMed ID: 24524051
[TBL] [Abstract][Full Text] [Related]
19. Quantifying the broader economic consequences of quadrivalent human papillomavirus (HPV) vaccination in Germany applying a government perspective framework.
Kotsopoulos N; Connolly MP; Remy V
Health Econ Rev; 2015 Dec; 5(1):54. PubMed ID: 26198884
[TBL] [Abstract][Full Text] [Related]
20. Estimating Public Economic Gains from Early Breast Cancer and Curative Treatment: A Case Study in Human Epidermal Growth Factor Receptor (HER-2) Positive Targeted Therapies.
Kommandantvold SA; Kotsopoulos N; Monteiro I; Ladeiras A; Hogan A; de Araujo FBM; Connolly MP
Oncol Ther; 2024 Jun; 12(2):277-292. PubMed ID: 38363526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
